Bank of America Starts Baxter (BAX) at Buy
BAX Hot Sheet
Rating Summary:9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Bank of America initiates coverage on Baxter (NYSE: BAX) with a Buy rating and $60 price target.
For more analyst ratings on BAX click here.
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
For more analyst ratings on BAX click here.
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
You May Also Be Interested In
- UPDATE: Barclays Starts MRC Global (MRC) at Overweight; Classic Rollup Story with Stable Recurring Revenue Stream
- Keefe, Bruyette & Woods Starts Oaktree Capital Group (OAK) at Market Perform
- Global Hunter Securities Starts Safe Bulkers (SB) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Bank of AmericaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
